Tnf Pharmaceuticals, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Q/C Technologies, Inc. has terminated its technology license agreement and is now fully concentrating its efforts on its optical processing unit initiative for AI inference.
Q/C Technologies, Inc. has dismissed its independent auditor, Stephano Slack LLC, and appointed Grassi & Co., CPAs, P.C., following prior audit reports that raised substantial doubt about the company's ability to continue as a going concern.
Q/C Technologies, Inc. announced the appointment of AI systems leader Chelsea Voss to its Board of Directors and a related consulting agreement.
Q/C Technologies, Inc. announced a consulting agreement with Ocean Avenue Holdings LLC, an entity affiliated with Martin Shkreli, who will serve as a Strategic Advisor.
Q/C Technologies, Inc. stockholders approved an increase in its equity incentive plan, a significant common stock issuance, and a potential reverse stock split.
Q/C Technologies, Inc. filed an amended 8-K to disclose previously omitted Restricted Stock Unit grants totaling 225,000 RSUs to its directors and officers.
Q/C Technologies, Inc. announced amendments to prior agreements, issued consulting warrants for 400,000 shares, and granted 200,000 restricted stock units to executives and directors.
Q/C Technologies, formerly TNF Pharmaceuticals, rebrands and changes ticker to QCLS, signaling a strategic pivot into quantum-class computing with exclusive rights to LightSolver's laser processing units for cryptocurrency.
TNF Pharmaceuticals closes a $7M private placement financing led by a strategic investor at a 44% premium to market.
TNF Pharmaceuticals, Inc. announces a strategic acquisition of LPU Holdings LLC and an exclusive technology license with LightSolver Ltd. to enter the cryptocurrency mining business.
TNF Pharmaceuticals announced a strategic pivot into cryptocurrency mining with exclusive rights to LightSolver's laser-based computing technology, supported by a $7 million private placement and a 1-for-100 reverse stock split.
TNF Pharmaceuticals, Inc. stockholders have approved significant amendments to the company's Certificate of Incorporation, including a substantial increase in authorized common stock and authorization for a reverse stock split, alongside the re-election of its board of directors.
TNF Pharmaceuticals amended its bylaws on May 9, 2025, to lower the required stockholder vote for matters other than director elections.
TNF Pharmaceuticals sets the date for its 2025 Annual Meeting of Stockholders and outlines the deadlines for shareholder proposals and director nominations.
TNF Pharmaceuticals received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting.
TNF Pharmaceuticals is prioritizing the development of Isomyosamine, an oral TNF-alpha inhibitor, for sarcopenia and muscle loss associated with GLP-1 agonist treatments.
8-K: TNF Pharmaceuticals Stockholders Approve Increase in Equity Incentive Plan Shares at Annual Meeting
TNF Pharmaceuticals' stockholders approved an increase of 2,259,060 shares to the company's equity incentive plan, bringing the total to 2,500,000 shares, at their annual meeting on November 25, 2024.
TNF Pharmaceuticals has secured a $600,000 strategic equity investment from Prevail Partners at a 20% premium to the 30-day VWAP, and will partner with Prevail InfoWorks for upcoming clinical trials.
TNF Pharmaceuticals has replaced its auditor, Morison Cogen LLP, with Stephano Slack LLC, following Morison Cogen's decision to cease providing audit services to publicly traded companies.
8-K: TNF Pharmaceuticals Sets Date for 2024 Annual Meeting and Outlines Proposal Submission Deadlines
TNF Pharmaceuticals has announced the date for its 2024 Annual Meeting of Stockholders and established deadlines for shareholder proposals and director nominations.
TNF Pharmaceuticals has amended the terms of its Series G Convertible Preferred Stock regarding the calculation of in-kind dividend payments.
TNF Pharmaceuticals has increased its authorized common stock from 16,666,666 to 250,000,000 shares after a special stockholder meeting on July 24, 2024.
MyMD Pharmaceuticals has rebranded to TNF Pharmaceuticals, reflecting its focus on TNF-alpha inhibition, and its stock will now trade under the ticker symbol TNFA.
8-K: MyMD Pharmaceuticals Increases Authorized Series G Preferred Stock to Facilitate Dividend Payments
MyMD Pharmaceuticals has amended its Series G Convertible Preferred Stock authorization, increasing the number of shares to enable potential dividend payments in the form of additional preferred stock.
MyMD Pharmaceuticals filed an amendment to its previous 8-K report to correct typographical errors related to the terms of preferred stock and warrants issued in recent private placements.
MyMD Pharmaceuticals has appointed a new President and Chief Medical Officer, added a new board member, and amended its Series G Convertible Preferred Stock agreement.
MyMD Pharmaceuticals completed a $14 million private placement, issuing Series G and F-1 Convertible Preferred Stock, along with warrants, to accredited investors.
MyMD Pharmaceuticals has secured an initial $14 million in a two-part funding round, with a potential for up to $42 million, from a new strategic investor and existing shareholders.
MyMD Pharmaceuticals announces the immediate resignation of its Chief Scientific Officer, Adam Kaplin, M.D., Ph.D., effective April 15, 2024.
MyMD Pharmaceuticals has amended the terms of its Series F Convertible Preferred Stock, deferring installment payments and granting preferred shareholders the right to elect a board member.